MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review
- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description – A detailed description of the company’s operations and business divisions.
Corporate strategy – Analyst’s summarization of the company’s business strategy.
SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history – Progression of key events associated with the company.
Major products and services – A list of major products, services and brands of the company.
Key competitors – A list of key competitors to the company.
Key employees – A list of the key executives of the company.
Executive biographies – A brief summary of the executives’ employment history.
Key operational heads – A list of personnel heading key departments/functions.
Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities – A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms such as DC vaccines to kill tumor cells; T-cell receptor (TCR) detect and efficiently kill tumor cells and T-cell-specific monoclonal antibodies, helps to remove unwanted T cells from the body MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company operates its operations in US, Europe and Asia. Medigene is headquartered in Martinsried, Germany.
MediGene AG Key Recent Developments
Jul 25, 2016: Medigene expands TCR platform technology with US patent for method for identification of CD4+ T cell antigens May 18, 2016: Medigene commissions EUFETS for cell production process for first own TCR studies May 12, 2016: Medigene reports results of first quarter 2016 Mar 17, 2016: Medigene announces management changes Mar 17, 2016: Medigene publishes annual report 2015: Cash increased substantially, financial guidance met
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers. The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research. Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company